239 related articles for article (PubMed ID: 21304051)
1. 2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.
Nagaprashantha LD; Vatsyayan R; Singhal J; Lelsani P; Prokai L; Awasthi S; Singhal SS
Carcinogenesis; 2011 Apr; 32(4):568-75. PubMed ID: 21304051
[TBL] [Abstract][Full Text] [Related]
2. 2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention.
Singhal SS; Singhal J; Figarola JL; Riggs A; Horne D; Awasthi S
Biochem Pharmacol; 2015 Aug; 96(3):151-8. PubMed ID: 25957660
[TBL] [Abstract][Full Text] [Related]
3. Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells.
Chintalapudi MR; Markiewicz M; Kose N; Dammai V; Champion KJ; Hoda RS; Trojanowska M; Hsu T
Carcinogenesis; 2008 Apr; 29(4):696-703. PubMed ID: 18212329
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
6. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
7. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
8. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
10. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
11. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
12. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
Peruzzi B; Athauda G; Bottaro DP
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
[TBL] [Abstract][Full Text] [Related]
14. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.
Yamasaki T; Kamba T; Kanno T; Inoue T; Shibasaki N; Arakaki R; Yamada T; Kondo K; Kamoto T; Nishiyama H; Ogawa O; Nakamura E
Cancer Sci; 2012 Nov; 103(11):2027-37. PubMed ID: 22931246
[TBL] [Abstract][Full Text] [Related]
15. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
18. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
19. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.
Gervais ML; Henry PC; Saravanan A; Burry TN; Gallie BL; Jewett MA; Hill RP; Evans AJ; Ohh M
Lab Invest; 2007 Dec; 87(12):1252-64. PubMed ID: 17906660
[TBL] [Abstract][Full Text] [Related]
20. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
Singhal J; Chikara S; Horne D; Salgia R; Awasthi S; Singhal SS
Mol Carcinog; 2018 Dec; 57(12):1751-1762. PubMed ID: 30136444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
